Controlled Release of Rhbmp-2 and Vancomycin from Nhac/Alpha-Csh Scaffold for Treatment of Chronic Osteomyelitis

Kezheng Mao,Jianheng Liu,Xiaojie Lian,Qingde Wang,Xiumei Wang,Wei Mei,Keya Mao
DOI: https://doi.org/10.1166/jbt.2015.1310
2015-01-01
Journal of Biomaterials and Tissue Engineering
Abstract:The treatment of contaminated and infected bone defects remains an intractable problem, and the ideal approach consists of simultaneously controlling the infection and repairing the bone defect. Thus, the development of an osteoconductive bone graft composite with antibiotic and growth factor release capabilities as well as osteogenesis-matched degradation properties is necessary. A new nano-hydroxyapatite/collagen/alpha-calcium sulfate hemihydrate (nHAC/alpha-CSH) composite consisting of vancomycin and recombinant human bone morphogenic protein-2 (rhBMP-2) was developed. The present study assessed its efficiency in vitro and in a rabbit femur defect model both in vitro and in vivo for treating chronic osteomyelitis induced by nnethicillin-resistant Staphylococcus aureus in a rabbit model. When immersed in phosphate-buffered saline, the pellets showed sustained vancomycin release over 15 days. The implants converted to a bone-like HA graft and supported the ingrowth of new bone into the femur defects within 12 weeks of implantation. Micro-computed tomography and histological analysis showed that the implants provided a cure for the bone infection. The results indicate that the rhBMP-2-vancomycin loaded nHAC/alpha-CSH implant, which combines sustained drug release and the ability to support new bone ingrowth, could provide a method for treating chronic osteomyelitis. This composite is a potential therapeutic agent for contaminated or infected bone defects due to its concomitant osteoinductive and antibiotic properties.
What problem does this paper attempt to address?